Silo Pharma Inc. (SILO)
Silo Pharma Statistics
Share Statistics
Silo Pharma has 4.48M shares outstanding. The number of shares has increased by 21.64% in one year.
| Shares Outstanding | 4.48M |
| Shares Change (YoY) | 21.64% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 4.29M |
| Failed to Deliver (FTD) Shares | 7.29K |
| FTD / Avg. Volume | 4.41% |
Short Selling Information
The latest short interest is 132.12K, so 2.95% of the outstanding shares have been sold short.
| Short Interest | 132.12K |
| Short % of Shares Out | 2.95% |
| Short % of Float | 3.07% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.75 and the forward PE ratio is null. Silo Pharma's PEG ratio is 0.89.
| PE Ratio | -0.75 |
| Forward PE | n/a |
| PS Ratio | 45.43 |
| Forward PS | 68.9 |
| PB Ratio | 0.65 |
| P/FCF Ratio | -0.85 |
| PEG Ratio | 0.89 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Silo Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.29, with a Debt / Equity ratio of 0.
| Current Ratio | 4.29 |
| Quick Ratio | 4.29 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | -925.59 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $24.03K |
| Profits Per Employee | $-1.46M |
| Employee Count | 3 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -45.69% in the last 52 weeks. The beta is 1.58, so Silo Pharma's price volatility has been higher than the market average.
| Beta | 1.58 |
| 52-Week Price Change | -45.69% |
| 50-Day Moving Average | 1.29 |
| 200-Day Moving Average | 1.3 |
| Relative Strength Index (RSI) | 39.81 |
| Average Volume (20 Days) | 165.26K |
Income Statement
In the last 12 months, Silo Pharma had revenue of 72.1K and earned -4.39M in profits. Earnings per share was -1.19.
| Revenue | 72.1K |
| Gross Profit | 66.26K |
| Operating Income | -4.71M |
| Net Income | -4.39M |
| EBITDA | -4.38M |
| EBIT | -4.39M |
| Earnings Per Share (EPS) | -1.19 |
Balance Sheet
The company has 3.91M in cash and 0 in debt, giving a net cash position of 3.91M.
| Cash & Cash Equivalents | 3.91M |
| Total Debt | 0 |
| Net Cash | 3.91M |
| Retained Earnings | -15.26M |
| Total Assets | 7.41M |
| Working Capital | 5.46M |
Cash Flow
In the last 12 months, operating cash flow was -3.83M and capital expenditures 0, giving a free cash flow of -3.83M.
| Operating Cash Flow | -3.83M |
| Capital Expenditures | 0 |
| Free Cash Flow | -3.83M |
| FCF Per Share | -1.04 |
Margins
Gross margin is 91.9%, with operating and profit margins of -6526.44% and -6092.59%.
| Gross Margin | 91.9% |
| Operating Margin | -6526.44% |
| Pretax Margin | -6092.59% |
| Profit Margin | -6092.59% |
| EBITDA Margin | -6076.96% |
| EBIT Margin | -6526.44% |
| FCF Margin | -5317.35% |
Dividends & Yields
SILO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for SILO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Sep 19, 2022. It was a backward split with a ratio of 1:50.
| Last Split Date | Sep 19, 2022 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | -2.82 |
| Piotroski F-Score | 3 |